Xilio Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters11-03

<a href="https://laohu8.com/S/XLO">Xilio Therapeutics</a> Inc <xlo.oq> expected to post a loss of 3 cents a share - Earnings Preview </xlo.oq>

Xilio Therapeutics Inc XLO.OQ XLO.O is expected to show a rise in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
The Waltham Massachusetts-based company is expected to report a 723.5% increase in revenue to $18.635 million from $2.26 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Xilio Therapeutics Inc is for a loss of 3 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 20.0% in the last three months.
Wall Street's median 12-month price target for Xilio Therapeutics Inc is $2.00, about 60.2% above its last closing price of $0.80

This summary was machine generated November 3 at 12:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580719290?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580719290","market":"us","top_or_hot":-1,"title":"Xilio Therapeutics Inc  expected to post a loss of 3 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/XLO\">Xilio Therapeutics</a> Inc <xlo.oq> expected to post a loss of 3 cents a share - Earnings Preview </xlo.oq></title></head><body><ul><li><p>Xilio <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>XLO.OQ</span> <span>XLO.O</span> is expected to  show a rise in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2025</p></li><li><p>The Waltham Massachusetts-based  company is expected to report a 723.5% increase in revenue to $18.635 million from $2.26 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Xilio Therapeutics Inc is for a loss of 3 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts had risen by about 20.0% in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Xilio Therapeutics Inc is $2.00, about 60.2% above its last closing price of $0.80</p></li></ul><p>This summary was machine generated November 3 at 12:31 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xilio Therapeutics Inc  expected to post a loss of 3 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXilio Therapeutics Inc  expected to post a loss of 3 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/XLO\">Xilio Therapeutics</a> Inc <xlo.oq> expected to post a loss of 3 cents a share - Earnings Preview </xlo.oq></title></head><body><ul><li><p>Xilio <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>XLO.OQ</span> <span>XLO.O</span> is expected to  show a rise in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2025</p></li><li><p>The Waltham Massachusetts-based  company is expected to report a 723.5% increase in revenue to $18.635 million from $2.26 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Xilio Therapeutics Inc is for a loss of 3 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts had risen by about 20.0% in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Xilio Therapeutics Inc is $2.00, about 60.2% above its last closing price of $0.80</p></li></ul><p>This summary was machine generated November 3 at 12:31 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF0Z6:1","article_id":"2580719290","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580719290","pubTimestamp":1762173115,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xilio Therapeutics Inc  expected to post a loss of3cents a share - Earnings Preview Xilio Therapeutics Inc XLO.OQ XLO.O is expected to  show a rise in quarterly revenue when it reports  results on Nov","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XLO":"XILIO THERAPEUTICS, INC."},"translate_title":"Xilio Therapeutics Inc预计每股亏损3美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLO":0.9},"content_text":"Xilio Therapeutics Inc  expected to post a loss of 3 cents a share - Earnings Preview Xilio Therapeutics Inc XLO.OQ XLO.O is expected to  show a rise in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2025The Waltham Massachusetts-based  company is expected to report a 723.5% increase in revenue to $18.635 million from $2.26 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.LSEG's mean analyst estimate for Xilio Therapeutics Inc is for a loss of 3 cents per share. The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts had risen by about 20.0% in the last three months. Wall Street's median 12-month price target for Xilio Therapeutics Inc is $2.00, about 60.2% above its last closing price of $0.80This summary was machine generated November 3 at 12:31 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580719290","isCrawlerRequest":true}